Sofosbuvir (GS-7977) in Combination With PEG and Ribavirin for 12 Weeks in Treatment Experienced Subjects With Chronic HCV Infection Genotype 2 or 3

Completed · Phase 2

Conditions studied: Hepatitis C

In brief

This study is to evaluate the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF) in combination with peginterferon alfa 2a (PEG) and ribavirin (RBV) administered for 12 weeks in participants with chronic genotype 2 or 3 hepatitis C virus (HCV) infection who have previously failed prior treatment with an interferon-based regimen.

Key facts

Study ID

NCT01808248

Run by

Gilead Sciences

People needed

47

Starts

2013-02-01

Expected to finish

2013-12-01

Last updated by the study team

2014-09-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Infection with genotype 2 or 3 HCV infection
• Cirrhosis determination
• Individual is treatment-experienced
• Screening laboratory values within defined thresholds
• Individual has not been treated with any investigational drug or device within 30 days of the Screening visit
• Use of highly effective contraception methods if female of childbearing potential or sexually active male

You may not qualify if…

• Prior exposure to a direct-acting antiviral drug targeting the HCV NS5B polymerase
• Pregnant or nursing female or male with pregnant female partner
• Current or prior history of clinical hepatic decompensation
• History of clinically-significant illness or any other major medical disorder that may interfere with treatment, assessment, or compliance with the study protocol
• Excessive alcohol ingestion or significant drug abuse

Where it is running

• Alamo Medical Research — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.